Chairman of the Board and Chief Executive Officer, Pfizer
Mr. Read is Chairman of the Board and Chief Executive Officer of Pfizer, one of the world’s premier innovative biopharmaceutical companies, which brings therapies to patients that significantly improve their lives. These include medicines, vaccines, and many of the world’s best-known consumer healthcare products.
Mr. Read’s career began with Pfizer in 1978, when he joined the company as an operational auditor. Over the next three decades, he assumed roles of increasing responsibility in Latin America, Canada, Europe, Africa, and the Middle East. Prior to being named CEO in December 2010, he served as group president of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units.
Mr. Read received his B.Sc. in chemical engineering from London University Imperial College and earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales. He serves on the boards of PhRMA, Kimberly-Clark and the Partnership for New York City.
Mr Ian C Read
President and Chief Executive Officer, Shionogi & Co. Ltd.
Dr. Isao Teshirogi is President and Chief Executive Officer of Shionogi & Co., Ltd., a major research-driven Japanese pharmaceutical company dedicated to its mission to “supply the best possible medicine to protect the health and wellbeing of the patients we serve.”
Dr. Teshirogi has been President and CEO of Shionogi & Co., Ltd. since April 2008, and a member of the Board of Directors since June 2002. He joined the Company in April 1982, after graduating from the University of Tokyo. After serving in U.S. branch offices, he was appointed Executive Corporate Officer and Executive General Manager of the Pharmaceutical R&D Division in 2004.
Dr. Teshirogi has served as Vice President of the Japan Pharmaceutical Manufacturers Association (JPMA) since May 2014, after having served as President of the Association for three years, during which time he launched the Asia-Pacific Pharma Congress (APAC) to support the development of the pharmaceutical industry across Asia, promoting collaboration in drug discovery and harmonization of pharmaceutical regulations. Dr. Teshirogi has also shown his commitment to the goal of eliminating infectious diseases, including neglected tropical diseases which can develop into global threats, through his support of the establishment of the Global Health Innovative Technology (GHIT) Fund as a charter member, in partnership with the Bill and Melinda Gates Foundation.
Dr. Teshirogi holds a Ph.D. in Pharmacology from the University of Tokyo.
Dr Isao Teshirogi
Chief Executive Officer, Roche Group
Severin Schwan was born in 1967 and is an Austrian citizen. After obtaining a degree in economics and a doctorate in law, Schwan began his career in 1993 at Roche Basel as a finance officer.
Following various management postings to Belgium, Germany and Switzerland, he moved to Singapore as regional head of the Roche Diagnostics business for Asia-Pacific in 2004. In 2006 Severin Schwan became CEO of Roche Diagnostics, the Roche Group’s global diagnostics business.
In March 2008 he was appointed CEO of the Roche Group and he became a member of the Roche Board in 2013.
Dr Severin Schwan